Equity-backed commitment dramatically de-risks pivotal program, boosts licensing appeal, and strengthens commercialization readiness.

HUNTINGTON, N.Y., Dec. 11, 2025 — Sen-Jam Pharmaceutical, a clinical-stage biotechnology company pioneering novel anti-inflammatory combination therapeutics, today announced a transformative partnership with TASK Clinical, a global contract research organization (CRO). Under the agreement, TASK Clinical will fund two-thirds of the upcoming Phase 3 clinical trial for SJP-001 in exchange for equity — an exceptionally rare commitment that significantly de-risks development, enhances investor confidence, and strengthens the program for global licensing opportunities.

This milestone follows Sen-Jam’s recent announcement appointing Rute Fernandes, a seasoned global life-sciences executive with leadership roles across Takeda, Shire, and Novartis, as Executive Advisor to accelerate commercialization pathways.

A Synergistic Partnership Network: TASK Clinical + KVK Tech

Sen-Jam now benefits from a vertically integrated development ecosystem:

• TASK Clinical providing clinical leadership and majority funding of Phase 3
• KVK Tech, Sen-Jam’s established corporate venture partner/CMO, driving formulation, CMC, and FDA submission readiness
• Rute Fernandes guiding global market expansion and commercialization strategy

KVK Tech has made significant progress in the formulation development and CMC work for SJP-001, including the manufacturing of GMP batches. Upon completion of the ongoing Phase 2 dose-ranging study, KVK Tech will finalize the FDA submission batches, enabling a rapid transition into Phase 3 and subsequent regulatory filing.

This powerful alignment ensures Sen-Jam is de-risked across clinical, manufacturing, operational, and commercial dimensions — a rare position for a company at this stage.

Quotes from Leadership

Jim Iversen, Co-Founder & CEO, Sen-Jam Pharmaceutical

“This partnership with TASK Clinical reflects a shared belief in the scientific and commercial potential of SJP-001. Having a global CRO take an equity position in our pivotal Phase 3 trial is a powerful signal to investors and future licensing partners. Combined with KVK Tech’s formulation and CMC execution and Rute’s commercial leadership, Sen-Jam is entering the strongest phase in its history.“

Johann de Bruyn, Chief Executive Officer, TASK Clinical

“We chose to invest directly in Sen-Jam and fund the majority of the Phase 3 program because we believe SJP-001 has the potential to be a first-in-category global therapy. It is uncommon for a CRO to assume an equity position in a pivotal trial, but Sen-Jam’s science, strategy, and team earned our confidence. We are proud to partner with Sen-Jam and look forward to executing a world-class Phase 3 study together.”

Rute Fernandes, Executive Advisor, Sen-Jam Pharmaceutical

“TASK Clinical’s commitment to fund the majority of Phase 3 is a powerful validation of Sen-Jam’s scientific foundation and strategic direction. I have rarely seen a CRO take such a substantial equity position in a sponsor’s pivotal program. The strength of this partnership, combined with the manufacturing readiness provided by KVK Tech, significantly de-risks SJP-001 for investors and accelerates our pathway to global licensing and commercialization. I am thrilled to help guide Sen-Jam in turning this momentum into widespread impact.“

SJP-001: A First-in-Category Opportunity

SJP-001 is Sen-Jam’s lead combination therapy designed to modulate the inflammatory cascade triggered by alcohol consumption — the underlying biological cause of next-day symptoms such as headache, malaise, nausea, and cognitive impairment. If approved, SJP-001 could become the first FDA-regulated hangover-prevention therapeutic, representing a first-in-category commercial opportunity in an underserved global market.

The Phase 2 trial, conducted by Cliantha Research in Toronto, Canada, was completed in November with data readout and final analysis expected Q1 2026.

Growing Visibility: Jackie Iversen’s TEDx Talk

Momentum continues to build through Co-Founder Jackie Iversen’s recent TEDx Talk “How Mastering Hangovers Reveals the Science of Longevity“, spotlighting the critical role of inflammation in human health and the urgent need for accessible, science-backed innovation. Her talk has broadened awareness of Sen-Jam’s mission, reinforcing the company’s leadership at the intersection of inflammation science and global health transformation.

A De-Risked, Licensing-Ready Therapeutics Company

Sen-Jam now represents one of the most attractive emerging assets in inflammation therapeutics, supported by:

• De-risked Phase 3 funding via TASK
• Manufacturing and regulatory readiness through KVK Tech
• Seasoned commercial leadership from Rute Fernandes
• Global thought leadership highlighted through TEDx
• A first-in-category therapeutic backed by robust scientific rationale

Together, these elements position Sen-Jam for accelerated investor engagement, strategic partnership development, and global licensing discussions.

About Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical is transforming the management of inflammation through novel, low-cost, combination therapeutics designed for safety, efficacy, and global accessibility. Its proprietary PAIR platform targets inflammatory cascades across acute and chronic conditions. Lead programs include SJP-001 for alcohol-induced inflammation and SJP-002C for viral respiratory symptoms. For more information, visit www.wefunder.com/senjam.

About TASK Clinical

TASK Clinical is a global contract research organization specializing in multi-site, late-phase clinical trials. With expertise spanning North America, Europe, and emerging markets, TASK delivers comprehensive development support and operational excellence to accelerate the approval and commercialization of innovative therapeutics.

About KVK Tech

KVK Tech is an FDA-approved pharmaceutical manufacturer specializing in formulation development, CMC execution, and large-scale commercial production. As Sen-Jam’s corporate venture partner, KVK Tech has led the formulation and CMC work for SJP-001 and will complete the FDA submission batches necessary for the upcoming Phase 3 program.

CONTACT INFORMATION:
Sen-Jam Pharmaceutical
Christine Leonard
781-913-1902
[email protected] 

SOURCE Sen-Jam Pharmaceutical

CHICAGO, Dec. 11, 2025 — Nurse Capital, a venture capital firm that invests in nurse-led startups, is pleased to announce a significant investment from its Fund I in RoddyMedical, Inc., a medical device innovator focused on developing products that enhance patient safety and improve staff effectiveness in clinical settings.

The Wauwatosa, WI-based startup’s flagship product, SecureMove-TLC^®, is a patented, wearable medical device designed to prevent medical tubing hazards that occur all too frequently in a hospital setting. The armband-style device secures and manages different types of medical tubes, lines and cords employed in patient care; and eliminates hazardous pulling and line/cord dislodgement during a patient’s therapy, transport, and movement. It can be worn for up to 30 days, and also provides nursing staff with more efficiency, convenience and time savings.

“Nurses don’t just see problems—they engineer solutions that work,” said Beth A. Brooks, PhD, RN, FACHE, Co-Founder of Nurse Capital. “Because nurses live the clinical realities day after day, their innovations are immediately usable and quickly adopted. SecureMove-TLC^® is exactly that kind of solution—designed from lived experience to reduce patient harm and improve workflow. RoddyMedical shows why investing in nurse-led innovation is both clinically smart and financially sound.”

One of the device’s key benefits is patient mobility. Getting patients up and moving during their hospital stay leads to earlier discharge, fewer hospital-acquired conditions, fewer readmissions, and significant hospital savings, noted RoddyMedical Founder and CEO Lindsey Roddy, RN, PhD(c). But it’s no easy task.

 “Therapy begins just hours after a major surgery, but is often inhibited by the number of tubes, lines, and cords attached to a patient in the ICU,” said Roddy. And those lines and cords can be dangerous. Recent studies have found that 19 million lines are pulled out every year from acute care patients, who can often be attached to up to 15 lines. Healthcare workers spend 64% of their time untangling and organizing lines when providing early mobility and therapy in the ICU. Healthcare facilities spend an additional $266 million each year replacing vascular access devices as a result of compromised lines and dislodgements. 

Roddy launched her startup in 2018 after she herself almost lost one of her patients in the ICU due to a medical tubing hazard. When assisting a patient getting out of bed after surgery for therapy, the line carrying the patient’s life support got caught and pulled out of his neck—an upsetting experience that drove her to find a better solution. Unable to find anything on the market that could have prevented this problem, Lindsey began to design a device that would prevent this from ever happening again. After several years in development, the startup introduced the SecureMove-TLC^® .

Currently, the device is being used in hospitals in six states including Mayo Clinic (Phoenix, AZ), Barnes Jewish (St. Louis, MO), and The Ohio State University Hospital, among others. It has also secured five global patents on its device.

“Nurse Capital is pleased to support nurse entrepreneurs like Lindsey Roddy as they bring their unique expertise to innovative solutions which better serve their patients,” said Nurse Capital Co-founder Marla J. Weston, PhD, RN.

RoddyMedical is now raising $5 million in Series A funding to expand its manufacturing capacity and market penetration.

About Nurse Capital

Nurse Capital is a nurse-founded and managed venture capital fund based in Chicago that makes early-stage investments in nurse entrepreneurs leading high-growth-potential businesses that are transforming the future of healthcare. Learn more at https://nursecapital.net/. 

About RoddyMedical, Inc.

RoddyMedical is a women founded and operated, Wisconsin based C-Corp, headquartered in Wauwatosa, WI, focused on developing innovative medical devices that improve clinical safety & patient outcomes. Its founding team has complementary experience in hospital-based patient care, medical device product design and development, manufacturing, and marketing. For more information, visit www.roddymedical.com.

SOURCE Nurse Capital

BASEL, Switzerland, Dec. 11, 2025 –Allegria Therapeutics (ALLEGRIA), a Swiss biotech company redefining the treatment landscape of therapeutics for mast cell-mediated diseases, announced today the successful completion of a USD 5.1 million seed extension financing.

The financing round was led by ALK Abelló, with participation of HighLight Capital (HLC), Lichtsteiner Foundation and co-founding investor Forty51 Ventures.

The investment sets the stage for accelerated growth and value creation for ALLEGRIA. The funds will be used to progress its lead program towards pre-clinical candidates in support of nomination its first clinical candidate, while at the same time meaningfully advancing its discovery-stage programs.

ALLEGRIA was founded in 2023. Since its inception, the company has established a highly experienced specialist core team and advisory board. ALLEGRIA is progressing a differentiated portfolio of proprietary therapeutic approaches and targets to selectively modulate mast cells. By leveraging its unique insights and strategy, it has identified differentiated molecules that have great promise for the development of transformative therapies with first-in-class and best-in-disease potential for the treatment of patients with allergies and related inflammatory conditions.

“Precision approaches offer the ability to target defined cell types and pathways to disrupt the pathogenic biology driving disease with optimal efficacy and safety” says Maria van Dongen, Ph.D., Co-founder and CEO. “By identifying the relevant pathways and targets in uncontrolled mast cell activation, and leveraging our extensive experience in drug development, we aim to bring more and better options to patients across numerous allergic and inflammatory diseases. The current financing round importantly supports us in that journey.”

ALK-Abelló (ALK), a global specialty pharmaceutical company focused on allergy and allergic asthma, is providing ALLEGRIA with a strong partner in the allergy space.

Peter Sejer Andersen, Ph.D., Senior Vice President of Global Research and Drug Discovery at ALK says: “Every year hundreds of millions are impacted by allergy, affecting their daily lives and potentially causing life threatening situations. Building on our strong heritage, our mission is to help five million people every year by 2030 through innovative and more effective solutions.” He continues: “We have followed ALLEGRIA’s development and have been repeatedly impressed with their advancements and team, as well as their highly original strategy for novel treatments for allergic disorders. Our investment in ALLEGRIA is well aligned with our Allergy+ strategy.”

Further, Henry He, Chief Investment Officer at HLC notes: “We are excited to be able to invest in ALLEGRIA, as the company is an excellent example of first-in-class therapeutic innovations that could significantly reduce the burden of several chronic diseases. Growing scientific and clinical insight shows that mast cells play an important role in a range of human pathologies. We look forward to supporting the further development of ALLEGRIA.“

ALLEGRIA collaborates with world leading partners in fundamental mast-cell biology, drug discovery and preclinical drug evaluation including Prof. Dr. Martin Metz, Managing Director of the Institute for Allergology at Berlin’s Charité and Ap. Prof. Dr. Philipp Starkl, Principal Investigator at the Medical University of Vienna.

Following this seed extension round, Dr. Peter Sejer Andersen has joined ALLEGRIA’s Board as non-executive director, thereby further strengthening the company’s leadership team.

ALLEGRIA is based in Basel, Switzerland, a broadly recognized hotspot for biotech and pharma.

ABOUT ALLEGRIA THERAPEUTICS

Allegria Therapeutics was founded in Basel, Switzerland by Forty51 Ventures in 2023. Pursuing a differentiated portfolio of proprietary therapeutic approaches and biological targets to selectively modulate mast cells, Allegria plans to redefine the treatment landscape for allergy and mast cell-mediated inflammatory diseases. For more information, please visit allegriatx.com.

ABOUT FORTY51 VENTURES

Forty51 Ventures is a venture capital firm with its core strategy focused on company formation in Biotech. Forty51 Ventures leads and co-leads early financing rounds of its growing portfolio which includes Pharma and Large Biotech spin-outs. www.forty51ventures.com

ABOUT ALK-ABELLÓ

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. ALK manufactures and markets allergy immunotherapy (‘AIT’) treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen.  Find more information at www.alk.net.

ABOUT HIGHLIGHT CAPITAL

HLC is a private investment firm dedicated to creating long-term value through promoting technology innovations. Leveraging deep expertise in chemical, biological and materials sciences and proprietary industry research, the firm invests in companies that enhance manufacturing efficiency and improve human wellness. HLC currently manages over USD 3.8 billion across key financial hubs, including Tokyo, Shanghai, Hong Kong and Boston. www.hlcfund.com 

ABOUT LICHTSTEINER FOUNDATION

The Lichtsteiner Foundation supports early-stage startups in the fields of medical technology, life science, mental health, public health, and wellbeing, to help pioneers bring their inventions to life. The foundation focuses on impact investing by providing funding in the form of equity. Check the website for more information: lichtsteinerfoundation.org or follow on LinkedIn.

Logo:- https://mma.prnewswire.com/media/2842790/Allegria_Therapeutics_Logo.jpg

SOURCE Allegria Therapeutics AG

Related Links

https://mma.prnewswire.com/media/2842790/ALLEGRIA_THERAPEUTICS.jpg
https://mma.prnewswire.com/media/2842790/ALLEGRIA_THERAPEUTICS.jpg

PHILADELPHIA, Dec. 11, 2025 — Ritten, a leading AI-powered system of record for behavioral health providers, today announced a $35 million USD Series B funding round led by Five Elms Capital with participation from existing investors Threshold Ventures, 8VC, Bienville Capital, and others. This investment will support Ritten’s expansion across mental health and addiction treatment providers spanning all levels of care.

“Behavioral health providers do extraordinary work in some of the most demanding care environments, and our team has always been dedicated to giving them the next generation of tools that reduce friction and improve care. Five Elms immediately understood our mission and approach,” said Noah Whitehead, CEO of Ritten. “This partnership with Five Elms will allow us to advance our AI-first roadmap, continue supporting clinicians and staff, and scale solutions that meet the nuanced requirements of behavioral health.”

Since its founding in 2020, Ritten has been dedicated to enabling behavioral health practitioners to deliver the highest quality care. By unifying electronic medical records, customer relationship management, and revenue cycle management into one modern AI-enabled platform, Ritten streamlines the entire patient and clinician journey, from referrals and admissions to scheduling, charting, compliance, and billing across both outpatient and residential settings. Ritten’s technology reduces toil and burnout for staff and drives operational efficiencies and growth for customer facilities.

Ryan Mandl, Partner at Five Elms, commented on the investment, “Ritten is revolutionizing a space that has long been underserved by fragmented, outdated technology. Their platform unifies the critical systems that practices need to grow, operate efficiently, and deliver high-quality treatment, enhanced by AI to meaningfully reduce complexity for care teams. We’re thrilled to be part of the next phase of Ritten’s growth.”

In addition to the acceleration of growth across the behavioral health space, Five Elms Capital’s investment in Ritten will contribute to further advancement of best-in-class AI capabilities for both practitioners and revenue cycle management. The company plans to continue to integrate AI-powered workflows throughout the platform, expand and mature their customer support offerings, and grow enterprise capabilities to meet the evolving needs of treatment organizations large and small.

About Ritten

Ritten is a unified behavioral health practice management platform purpose-built for substance use disorder and mental health treatment providers. The platform combines a robust EHR, integrated CRM, and comprehensive RCM into a single system of record, helping organizations streamline operations, remain compliant, and deliver higher-quality care. Founded in 2020 and headquartered in Philadelphia, Ritten serves treatment centers across the U.S., spanning single-site providers to multi-state enterprise groups. For more information, please visit ritten.io.

About Five Elms Capital

Five Elms Capital is a growth investor in software businesses that users love, providing capital and resources to help companies accelerate growth and further cement their role as industry leaders.

With over $3 billion in assets under management and a team of over 80 professionals, Five Elms has invested in more than 70 software platforms worldwide. Beyond providing capital, Five Elms delivers strategic and operational expertise, focused on executing initiatives that move the needle on growth, retention, product, and AI to set companies up for long-term success. For more information, visit fiveelms.com.

SOURCE Five Elms Capital

Now valued at $5.5 billion, Harness will use the new capital to advance Harness AI and accelerate platform expansion and global GTM momentum.

SAN FRANCISCO, Dec. 11, 2025 — Harness, the AI Software Delivery Platform company, today announced a $240 million Series E financing round. The financing round is comprised of a $200 million investment led by Goldman Sachs Alternatives and a planned $40 million tender offer with participation from IVP, Menlo Ventures, and Unusual Ventures. This investment values Harness at $5.5 billion and reflects the accelerating demand for a unified, AI-native platform for software delivery.

While AI is transforming how software is written, that work represents only the beginning of the engineering lifecycle. Most teams spend just 30–40% of their time writing and iterating on code; the remaining 60–70% goes to the “outer loop” — testing, deployments, security, compliance, and optimization. These workflows are deeply interconnected and remain highly manual, creating friction that slows velocity. Harness is bringing AI and automation to this outer loop, turning the most complex and time-consuming parts of software delivery into intelligent, streamlined processes.

Now, AI is amplifying the pressure exponentially. Code volume is accelerating — in many cases by 4x — and every line must still be tested, secured, deployed, and maintained. The surge of AI-generated code is further widening the gap between rapid development and the safe, reliable delivery of software. Organizations increasingly need intelligence and automation that can manage the entire after-code lifecycle — and Harness provides the platform that brings these AI capabilities together.

“The next frontier for AI in software engineering is applying intelligence to the delivery process — testing, verification, deployments, governance, and everything that happens after code is written,” said Jyoti Bansal, cofounder and CEO of Harness. “Our customers are moving faster than ever with AI, but the delivery process is where complexity and risk pile up. Harness is leading the way in bringing clarity, automation, and control to this part of the lifecycle so teams can ship software quickly, safely, and reliably at scale.”

Harness: The AI Software Delivery Platform

The new investment will help accelerate the evolution of Harness AI, a unified system purpose-built for everything after code. Harness AI is designed to eliminate the downstream bottlenecks that slow down engineering velocity. By combining specialized AI agents, deep organizational context, and reliable orchestration, the platform turns software delivery workflows into an intelligent system that learns, adapts, and acts on behalf of engineering teams.

Harness AI is built with three foundational layers that bring intelligent automation to the software development lifecycle:

• AI Agents purpose-built for software delivery: A library of focused agents that perform delivery, testing, verification, security, governance, and operational tasks — removing the manual coordination traditionally required across teams and tools.
• The Software Delivery Knowledge Graph: A unified context model mapping code changes, services, deployments, tests, environments, incidents, policies, and cost signals. This layer makes AI precise, trustworthy, and aligned to each customer’s architecture and workflows.
• Enterprise-grade orchestration engine: A reliable execution engine that transforms AI-driven insight into consistent automation across pipelines and environments, ensuring decisions are evaluated and implemented safely and predictably.

With deep organization-specific context, every action taken by Harness AI is precise and aligned to each customer’s architecture and workflows. Issues are identified earlier, evaluated with full context, and resolved before they reach production. Teams ship faster, not because they accept more risk, but because the platform absorbs the complexity on their behalf.

These capabilities are already driving measurable outcomes for Harness’s 1,000+ enterprise customers:

• United Airlines accelerated deployment times by 75% and migrated 80% of workloads to the cloud.
• Morningstar modernized its CI/CD ecosystem, achieving 5x faster builds, consolidating 36,000 pipelines to 50 templates, and transitioning from weeks-long releases to daily deployments.
• Keller Williams increased deployment frequency by 6x and saved 3 weeks in every release cycle.
• National Australia Bank (NAB) reduced build times by 67% and improved troubleshooting efficiency by 85%.

“AI has shifted the bottleneck from writing code to delivering it, and Harness is solving that problem at enterprise scale,” said Beat Cabiallavetta, Partner at Goldman Sachs Alternatives. “Their unified platform — combining AI, context, governance, and security — is resonating with organizations redesigning their engineering systems for the AI era. Harness is helping shape the future of modern software delivery.”

Harness Momentum

This next era of software delivery is already taking shape across Harness’s customer base, reflected in the scale, adoption, and global momentum Harness has built over the past year:

• ARR Growth: On track to exceed $250M ARR in 2025, with 50%+ YoY growth.
• Platform Scale: Powered 128M deployments, 81M builds, 1.2T API calls protected, and $1.9B in cloud spend optimization for customers over the last 12 months.
• Enterprise Adoption: Trusted by 1,000+ enterprise engineering teams across North America, EMEA, and APAC.
• Global Expansion: Grown to a 1,200+ employee team across 14 offices worldwide.
• Industry Recognition: Named to leading innovation and workplace lists, including the Forbes Cloud 100, Fast Company’s Best Workplaces for Innovators, and Inc. Magazine Power Partners.

Harness will use the Series E funding to accelerate platform innovation, expand its global footprint, and advance its vision for a world where the process of getting code to production is automated, secure, resilient, and governed by design.

To learn more about Harness and the future of AI software delivery, visit harness.io.

About Harness
Harness is the AI DevOps Platform™ company, enabling engineering teams to build, test, and deliver software faster and more securely. Powered by Harness AI and the Software Delivery Knowledge Graph, the platform brings intelligent automation to every stage of the software delivery lifecycle after code—removing toil and freeing developers from manual, repetitive work. Companies like United Airlines and Choice Hotels use Harness to accelerate releases by up to 75%, cut cloud costs by 60%, and achieve 10x efficiency across DevOps. Based in San Francisco, Harness is backed by Menlo Ventures, IVP, Unusual Ventures, and Citi Ventures.

About Goldman Sachs Alternatives 
Goldman Sachs (NYSE: GS) is one of the leading investors in alternatives globally, with over $500 billion in assets and more than 30 years of experience. The business invests in the full spectrum of alternatives including private equity, growth equity, private credit, real estate, infrastructure, sustainability, and hedge funds. Clients access these solutions through direct strategies, customized partnerships, and open-architecture programs.

The business is driven by a focus on partnership and shared success with its clients, seeking to deliver long-term investment performance drawing on its global network and deep expertise across industries and markets.

The alternative investments platform is part of Goldman Sachs Asset Management, which delivers investment and advisory services across public and private markets for the world’s leading institutions, financial advisors and individuals. Goldman Sachs has approximately $3.5 trillion in assets under supervision globally as of September 30, 2025.

Follow us on LinkedIn.

SOURCE Harness

BOSTON, Dec. 11, 2025 — OnCorps AI, a leading agentic AI platform for fund operations, has secured $55 million in growth capital from Long Ridge Equity Partners, a growth equity firm with deep experience in financial and business technology. The company will use the capital to accelerate product innovation, expand go-to-market teams, and scale infrastructure to support its rapidly growing customer base.

Founded in 2011, OnCorps AI delivers intelligent exception resolution for fund operations, primarily serving asset managers and fund administrators. Beyond detecting discrepancies in trade reconciliations and fund documentation, the platform autonomously investigates root causes, provides recommendations for issue resolution, and learns from patterns to prevent future breaks. 

“We’ve been running complex AI solutions in production for the world’s largest asset managers for several years, giving us a meaningful advantage in delivering tangible returns from AI,” said Bob Suh, Founder of OnCorps AI. “Every day, our systems close exceptions, reconcile trades, and oversee trillions in assets with high accuracy and low error rates. With Long Ridge’s investment, we can expand these capabilities across the broader industry.”

OnCorps’ specialized AI agents are trained on millions of real-world data discrepancies and exceptions across trade processing, fund accounting, and reporting workflows. This deep domain training, coupled with continuous learning from production environments, enables OnCorps to achieve accuracy rates and exception resolution times that general-purpose automation tools cannot match. 

Asset management operating margins have fallen in recent years, driven by surging transaction volumes, heightened regulatory requirements, and persistent fee compression. In an effort to drive efficiency, PIMCO, GMO, and other leading institutions – representing $13 trillion in assets – are turning to OnCorps to reduce manual effort and streamline their fund operations. 

In connection with the investment, Long Ridge Managing Partners Jim Brown and Kevin Bhatt will join the OnCorps AI Board of Directors.

“OnCorps AI has built the market-leading AI platform for fund operations,” said Jim Brown. “Their production-ready agents are trained on domain-specific data and workflows, delivering immediate operational value. We are excited to partner with Bob and the OnCorps team as they scale the business.”

The funding will enable OnCorps to expand into adjacent capital markets workflows where clients face similar challenges, including cash management, regulatory reporting, and complex trade processing.

Today, OnCorps provides customers with:

• AI-First Reconciliations: Leverages deep research agents to accelerate reconciliation processes by automating data matching, review, and investigation, reducing manual effort and cycle time.
• AI-First Reporting Reviews: Enables asset managers and service providers to automate and streamline the review of quarterly, semi-annual and annual financial reports, improving accuracy, consistency, and efficiency.

TD Securities served as OnCorps’ lead financial advisor. Altman Solon was the consulting partner. Goodwin Procter acted as legal counsel to Long Ridge, and Sidley Austin LLP served as legal counsel to OnCorps.

About OnCorps AI

OnCorps AI is a leading agentic AI platform for fund operations. The company delivers intelligent exception resolution for trade reconciliations, fund reporting, and related operational workflows. By optimizing the investigation and resolution of complex exceptions, OnCorps drives efficiency and risk reduction for asset managers and fund administrators. For more information, visit www.oncorps.ai.

About Long Ridge Equity Partners

Founded in 2007, Long Ridge Equity Partners is a private investment firm focused on the financial and business technology sectors. Leveraging deep sector knowledge and an extensive network of industry resources, Long Ridge serves as a value-added partner to high-growth businesses. Since its founding, Long Ridge has sponsored many successful growth companies in the financial and business technology sectors, providing founders and management teams with partnership, strategic resources, and capital to drive profitable expansion. Long Ridge manages over $1.75 billion of committed capital. For more information on Long Ridge Equity Partners, please visit www.long-ridge.com.

SOURCE OnCorps AI

HIRO Capital da la bienvenida a Sir Nick Clegg como socio general y lanza el fondo de capital de riesgo europeo HIRO III con un nuevo consejo asesor compuesto por líderes globales, incluido Yann LeCun

LONDRES, 10 de diciembre de 2025 — Sir Nick Clegg, Yann LeCun y otros se unen a HIRO III, un VC de múltiples etapas centrado en Reino Unido y Europa, centrado en IA espacial, robótica, longevidad, juegos, espacio y defensa.

HIRO Capital, firma de capital de riesgo liderada por sus fundadores, anunció hoy que Sir Nick Clegg, expresidente de Asuntos Globales de META y exviceprimer ministro del Reino Unido, se ha unido al Fondo como Socio General para el lanzamiento de HIRO III. HIRO III es un gran fondo multietapa con capacidad para invertir entre 5 y 50 millones de euros en cada uno de los proyectos innovadores más prometedores, cubriendo la brecha de capital para empresas de escalamiento en Reino Unido y Europa.

El equipo fundador de HIRO, compuesto por Luke Alvarez, Cherry Freeman y la leyenda británica de los videojuegos, Sir Ian Livingstone CBE, cuenta con una sólida trayectoria como emprendedores fundadores, con múltiples salidas a bolsa e IPO que suman más de 10.000 millones de euros. Esta trayectoria se ha cimentado en la experiencia técnica y el conocimiento de las empresas de crecimiento, fruto de décadas de desarrollo e inversión en empresas emergentes.

Las bases de HIRO como inversor en computación espacial lo posicionan perfectamente para la nueva era de la tecnología en la que veremos una creación de valor extraordinaria en toda Europa en áreas que van desde la IA espacial y la robótica hasta la defensa y la longevidad.

Sir Nick Clegg afirmó: “Me uní a HIRO porque comparto con los fundadores la creencia en el auge de la computación inmersiva y la IA espacial. Pasaremos de estar mirando internet a vivir en internet. Nos encontramos en las primeras etapas de ese cambio de plataforma con la convergencia de las tecnologías espaciales y la IA de modelos mundiales de próxima generación. A diferencia de otros fondos, HIRO se centra totalmente en estos temas, íntegramente en Europa”.

“Este es un momento de oportunidad increíble para el ecosistema tecnológico del Reino Unido y Europa. Contamos con algunos de los investigadores y universidades más destacados del planeta, además de grandes ingenieros y emprendedores. Nuestro problema no es la falta de innovación, sino la falta de capital a gran escala. Europa puede tener sus críticos, pero contamos con un vibrante panorama de empresas emergentes que ahora está listo para impulsar su crecimiento. Creo que el equipo de HIRO tiene el alcance geográfico y tecnológico único para contribuir a que esto suceda.”

Junto con este nombramiento, el equipo de HIRO se verá reforzado por el nuevo Consejo Asesor. Este consejo aporta una experiencia excepcional en cada uno de los cuatro temas centrales de la tesis de HIRO: IA Espacial y Nube, Autonomía y Robótica, Espacio y Defensa, y Aumento y Longevidad.

El profesor Yann LeCun afirmó: “Estoy encantado de unirme al Consejo Asesor de HIRO. Estamos entrando en una nueva fase de la IA: una era de sistemas capaces de comprender el mundo físico, con memoria persistente y capaces de razonar y planificar acciones complejas. La trayectoria de HIRO en inversiones en tecnologías espaciales, tecnología 3D, dispositivos portátiles y videojuegos la posiciona excepcionalmente bien para aprovechar esta nueva ola de oportunidades en Europa”.

La nueva junta incluye al profesor Yann LeCun, ex científico jefe de Meta y ganador del premio Turing por inteligencia artificial de aprendizaje profundo; Malcolm Turnbull, ex primer ministro de Australia y un importante inversor en tecnología; el mayor Tim Peake, científico, piloto de pruebas y el primer astronauta británico de la ESA; Laurent Solly, vicepresidente de Europa en META; el experto en seguridad y defensa, el profesor Deeph Chana de Imperial, Londres, director fundador de NATO DIANA y el Fondo de Innovación de la OTAN; Hannah Gladman, Estrategia y Proyectos Especiales en Google DeepMind; el Dr. Jack Scannell, inversor en biotecnología, fundador de longevidad, creador de la Ley de Eroom; Edward van Cutsem, presidente de Mercados Privados en Westerly Winds y ex director general de BlackRock; el profesor Paul Newman, profesor de Ingeniería de la Información en Oxford y fundador del Oxford Robotics Institute; Caroline Daniel, ex periodista y estratega del Financial Times; y Loredana Crisan, directora de diseño en Figma.

Luke Alvarez, socio director de HIRO, afirmó: “Me complace dar la bienvenida a Sir Nick a nuestro equipo, junto con Yann y los demás miembros de nuestro extraordinario Consejo Asesor. Hoy nos encontramos en las primeras etapas de una explosión cámbrica de nuevas tecnologías, impulsada por la creciente convergencia de la informática con el mundo físico, el cuerpo humano y los agentes autónomos. Todos compartimos la misma convicción en el potencial de Europa para estar a la vanguardia tecnológica y la misma pasión por contribuir al éxito de Reino Unido y Europa. Nuestro nuevo Consejo Asesor ha sido seleccionado por su visión, su experiencia tecnológica y sus redes a nivel mundial y europeo. Esperamos anunciar las primeras inversiones de HIRO III en 2026”.

Acerca de HIRO Capital  

HIRO Capital es una firma de capital de riesgo con sede en Londres y Luxemburgo, liderada por sus fundadores, que invierte en el futuro superabundante de la humanidad. HIRO invierte desde la Serie A hasta la Serie C (estrategias de expansión) en nuestros sectores temáticos especializados de IA, computación espacial, autonomía, robótica, longevidad, aumento de capital, videojuegos, simulación y tecnologías espaciales y de defensa. Nos centramos en emprendedores e innovadores de la amplia región Europa+, que incluye la UE, Reino Unido, Noruega, Suiza y Ucrania. Somos fundadores y líderes que apoyamos a líderes fundadores. Somos optimistas y futuristas. Creemos que Europa+ puede y debe ser un líder global en la próxima fase de la evolución humana, impulsada por la tecnología. Sabemos que la creatividad, la ambición y el emprendimiento de las personas construirán mejores sociedades humanas. https://hiro.capital/  

HIRO recibe su nombre del héroe en el que te conviertes cuando juegas un juego o deporte; del héroe que eres cuando creas una empresa; y rinde homenaje a Hiro Protagonist, el héroe hacker de Snow Crash de Neal Stephenson, que codifica el mundo digital 3D y salva a la humanidad contra todo pronóstico.

Logo – https://mma.prnewswire.com/media/2842654/HIRO_Capital_Logo.jpg

LONDRES, 10 décembre 2025 — Sir Nick Clegg, Yann LeCun et d’autres personnalités rejoignent HIRO III, une société de capital-risque multiniveau axée sur le Royaume-Uni et l’Europe, qui se concentre sur l’IA spatiale, la robotique, la longévité, les jeux, l’espace et la défense.

HIRO Capital, une société de capital-risque dirigée par ses fondateurs, a annoncé aujourd’hui que Sir Nick Clegg, ancien président des affaires mondiales de META et ancien vice-Premier ministre du Royaume-Uni, avait fait son entrée dans le fonds comme associé général en vue du lancement de HIRO III. HIRO III est un grand fonds multiniveau capable de déployer entre 5 et 50 millions d’euros par niveau dans des innovateurs prometteurs, en ciblant le manque de capital des entreprises en croissance au Royaume-Uni et en Europe.

À l’origine de nombreuses sorties et introductions en bourse pour un total de plus de 10 milliards d’euros, les fondateurs de HIRO, Luke Alvarez, Cherry Freeman et Sir Ian Livingstone, Commandeur de l’Ordre de l’Empire britannique et légende des jeux vidéo au Royaume-Uni, sont des entrepreneurs au riche palmarès. Ces réussites sont le fruit de compétences techniques et d’un certain savoir-faire en matière de croissance d’entreprise, acquis au cours de décennies de création de jeunes pousses et d’investissement dans ces dernières. 

La base d’investissement de HIRO dans l’informatique spatiale positionnent parfaitement la société pour la nouvelle ère technologique, qui verra une création de valeur extraordinaire à travers l’Europe dans des domaines allant de l’IA spatiale à la robotique, en passant par la défense et la longévité.

Sir Nick Clegg a déclaré : « J’ai intégré HIRO parce que je partage avec ses fondateurs la conviction que l’informatique immersive et l’IA spatiale sont en plein essor. Nous allons cesser de regarder l’internet pour vivre dans l’internet. Avec la convergence des technologies spatiales et des modèles mondiaux d’IA de nouvelle génération, nous sommes au tout début de ce changement de plateforme. Contrairement à d’autres fonds, HIRO se concentre entièrement sur ces thèmes, exclusivement en Europe.

Il s’agit d’une occasion merveilleuse pour l’écosystème technologique du Royaume-Uni et de l’Europe. Nous disposons de chercheurs et d’universités parmi les plus remarquables de la planète, ainsi que d’ingénieurs et d’entrepreneurs de premier plan. Notre problème n’est pas un manque d’innovation, c’est un manque de capital à grande échelle. L’Europe peut avoir ses détracteurs, mais nous y avons de jeunes entreprises dynamiques qui sont désormais prêtes à passer au niveau supérieur, et je crois que la portée géographique et technologique unique de l’équipe de HIRO pourra les aider à sauter le pas. »

Parallèlement à cette nomination, l’équipe de HIRO sera renforcée par son nouveau comité consultatif. Celui-ci enrichira de ses connaissances exceptionnelles chacun des quatre domaines thématiques centraux de HIRO : IA spatiale et informatique en nuage, autonomie et robotique, espace et défense, augmentation et longévité.

Le professeur Yann LeCun a commenté : « Je suis ravi d’entrer au comité consultatif de HIRO. Nous sommes à l’aube d’une nouvelle phase de l’IA, une ère dans laquelle les systèmes seront capables de comprendre le monde physique, intégreront une mémoire persistante et pourront raisonner et planifier des actions complexes. Le bilan de HIRO en matière d’investissement dans les technologies spatiales, les technologies en 3D, les objets connectés et les jeux qualifie remarquablement la société pour tirer parti de cette nouvelle vague de perspectives en Europe. »

Le nouveau comité comprend les membres suivants : le professeur Yann LeCun, ancien directeur scientifique de Meta et lauréat du prix Turing pour l’IA d’apprentissage profond ; Malcolm Turnbull, ancien Premier ministre d’Australie et investisseur technologique de premier plan ; le commandant Tim Peake, scientifique, pilote d’essai et premier astronaute britannique de l’ESA ; Laurent Solly, vice-président de META pour l’Europe ; le professeur Deeph Chana, expert en sécurité et en défense de l’Imperial College de Londres, directeur fondateur de l’Accélérateur d’innovation de défense pour l’Atlantique Nord (DIANA) au sein de l’OTAN et du Fonds OTAN pour l’innovation ; Hannah Gladman, responsable de la stratégie et des projets spéciaux chez Google DeepMind ; Jack Scannell, investisseur en biotechnologie, fondateur du concept de longévité, créateur de la loi d’erooM ; Edward van Cutsem, président des marchés privés chez Westerly Winds et ancien directeur général de BlackRock ; Paul Newman, professeur d’ingénierie de l’information à Oxford et fondateur de l’Oxford Robotics Institute ; Caroline Daniel, ancienne journaliste et stratège du Financial Times ; et Loredana Crisan, directrice de la conception chez Figma.

Luke Alvarez, associé directeur de HIRO, a ajouté : « Je suis enchanté d’accueillir Sir Nick au sein de notre équipe, ainsi que Yann et les autres formidables membres de notre comité consultatif. Nous vivons actuellement les prémices d’un big bang de nouvelles technologies, alimentées par l’accélération de la convergence entre l’informatique et le monde physique, le corps humain et les agents autonomes. Nous partageons tous la même conviction que l’Europe peut être à la pointe de la technologie, et la même ambition de jouer un rôle dans la réussite du Royaume-Uni et de l’Europe. Notre nouveau comité consultatif a été sélectionné pour sa vision, ses compétences technologiques, son réseau aux niveaux mondial et européen. Nous sommes impatients d’annoncer les premiers investissements de HIRO III en 2026. »

À propos de HIRO Capital

HIRO Capital est une société de capital-risque basée à Londres et à Luxembourg, dirigée par ses fondateurs, qui investit dans l’avenir surabondant de l’humanité. HIRO investit de la série A à la série C, dans des entreprises en croissance relevant de nos secteurs thématiques de spécialité que sont l’IA, l’informatique spatiale, l’autonomie, la robotique, la longévité, l’augmentation, les jeux, la simulation et les technologies de l’espace et de la défense. Nous nous concentrons sur les entrepreneurs et les innovateurs de la grande région Europe+, qui comprend l’UE, le Royaume-Uni, la Norvège, la Suisse et l’Ukraine. Nous sommes nous-mêmes des fondateurs et des dirigeants qui soutenons des fondateurs dirigeants. Nous sommes optimistes et futuristes. Nous pensons que l’Europe+ peut et doit être un leader mondial dans la prochaine phase de l’évolution humaine, rendue possible par la technologie. Nous savons que la créativité, l’ambition et l’esprit d’entreprise de chaque personne peuvent construire de meilleures sociétés humaines. https://hiro.capital/

HIRO porte le nom du héros que l’on devient quand on joue à un jeu ou que l’on pratique un sport, du héros que l’on est lorsqu’on crée une entreprise. C’est un hommage à Hiro Protagoniste, héros du roman « Le Samouraï virtuel » de Neal Stephenson, un pirate informatique qui code le monde numérique en 3D et sauve l’humanité de l’adversité.

Logo – https://mma.prnewswire.com/media/2842654/HIRO_Capital_Logo.jpg

Recent funding round, led by Hudson Bay Capital, fuels expanded capacity and commercialization of formulated intermediates across oil & gas, mining, agriculture and industrial & CPG markets

SOLON, Ohio, Dec. 10, 2025 — Locus Fermentation Solutions (Locus FS), a U.S.-based biotechnology company producing performance-enhancing bio-based additives, today announced the close of an oversubscribed $20 million investment in a convertible note round at an equity valuation of $100M led by Hudson Bay Capital, with the opportunity to up-size the round. The capital will be used to expand the company’s domestic biomanufacturing capacity, accelerate commercial activities and product development across four strategic sectors: oil & gas, mining, agriculture, and industrial/CPG formulations. 

This latest round brings total funding this year to over $40 million in growth capital and includes participation from company leadership.

“This funding signals strong confidence in the future of Locus Fermentation Solutions,” said John Uhran, CEO of Locus FS. “Building on strong double-digit growth, including the acquisition of over 50 new customers in 2025, we have the team, technology and the financial momentum to scale what we do best—formulate and manufacture better performing, cleaner and more effective alternatives to traditional chemistry using our proprietary biomanufacturing platforms and glycolipid molecules.”

Investing in the Future of USA-Made, Bio-based Chemistry

With increasing emphasis on domestic manufacturing and supply chain resiliency, Locus FS is uniquely positioned as the only U.S. producer of glycolipid biosurfactants with TSCA approval for commercial-scale volumes. These non-GMO, palm-free bio-based ingredients deliver powerful surface activity and improved performance, with dramatically lower toxicity and greater biodegradability than conventional surfactants, making them ideal for replacing petrochemical-based formulations across multiple industries.

The newly secured funds will support:

• Expansion of U.S. fermentation and downstream processing capacity
• Commercial growth and customer acquisition across key markets
• Acceleration of commercialization efforts and new product launches
• Leveraging the company’s deep patent portfolio to drive innovation
• Deployment of digital tools and analytics to optimize business performance

“We’re seeing a global push toward performance-based sustainability in formulations—and Locus FS is delivering exactly that,” said Matt Russell at Hudson Bay Capital. “The company’s glycolipids and microbials aren’t just ‘green’—they’re engineered to outperform conventional options and are already being used successfully at scale.”

Positioned for Scaled Impact

Locus FS has already achieved strong commercial traction and technical validation across its focus markets:

• In Oil & Gas, the company’s glycolipid-enhanced treatments have enabled operators to substantially boost production while complying with strict environmental regulations.
• In Mining, Locus biosurfactants deliver improved metal and mineral recovery while increasing efficiency in leaching and flotation operations.
• In Agriculture, the company’s biologicals & glycolipid-based treatments consistently boost crop yields and farmer ROI, with statistically significant results in eight top-growing crops.
• In industrial and CPG formulations, Locus glycolipids help formulators reduce surfactant load and enhance performance while meeting clean-label and ESG targets.

With the addition of this new funding, Locus FS will continue building on its market leadership by launching new products, expanding distribution and partnering with companies looking to replace traditional chemistries with bio-based, high-performance alternatives. For more information, visit Locusfs.com.

About Locus Fermentation Solutions (Locus FS)
Locus Fermentation Solutions (Locus FS) is a USA-based biotechnology company delivering high-performance specialty chemical formulations enhanced with novel glycolipids and microbial blends. Built on deep microbial expertise, the company develops bio-based additives that act as powerful formulation amplifiers—pushing performance beyond the limits of traditional chemistry across industrial, CPG, energy, mining and agricultural applications. With a proprietary biomanufacturing platform and science-first approach, Locus FS helps customers solve complex formulation challenges and accelerate the transition to smarter, more sustainable solutions. Visit Locusfs.com to learn more.

SOURCE Locus Fermentation Solutions